Agenus reports fourth quarter and full year 2023 results

Lexington, mass.--(business wire)--agenus inc. (“agenus”) (nasdaq: agen), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the fourth quarter and full year 2023. “in 2023, agenus made significant advances across our bot/bal development program. our first target indication is metastatic, refractory colorectal cancer that is not msi-h/dmmr, for which we are focused on pursuing accelerat.
AGEN Ratings Summary
AGEN Quant Ranking